Genetic and compound screens uncover factors modulating cancer cell response to indisulam.
Journal
Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
22
12
2021
revised:
26
04
2022
accepted:
26
04
2022
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
12
5
2022
Statut:
epublish
Résumé
Discovering biomarkers of drug response and finding powerful drug combinations can support the reuse of previously abandoned cancer drugs in the clinic. Indisulam is an abandoned drug that acts as a molecular glue, inducing degradation of splicing factor RBM39 through interaction with CRL4
Identifiants
pubmed: 35534224
pii: 5/9/e202101348
doi: 10.26508/lsa.202101348
pmc: PMC9095732
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Intracellular Signaling Peptides and Proteins
0
N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide
0
RNA Splicing Factors
0
Sulfonamides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022 Pogacar et al.
Références
Cell Rep. 2019 Nov 5;29(6):1499-1510.e6
pubmed: 31693891
Nat Biotechnol. 2019 Aug;37(8):907-915
pubmed: 31375807
EMBO J. 1996 Jan 15;15(2):265-75
pubmed: 8617202
Cell Res. 2018 Jun;28(6):690-692
pubmed: 29507396
Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5593-601
pubmed: 25480548
Clin Cancer Res. 2003 Nov 1;9(14):5195-204
pubmed: 14613999
Ann Oncol. 2001 Sep;12(9):1289-93
pubmed: 11697842
Eur J Cancer. 2003 May;39(8):1097-104
pubmed: 12736109
Mol Cell. 2020 Mar 5;77(5):1092-1106.e9
pubmed: 31973889
Signal Transduct Target Ther. 2020 Jul 2;5(1):113
pubmed: 32616710
Nucleic Acids Res. 2014 Dec 16;42(22):e168
pubmed: 25300484
Cancer Cell. 2019 Mar 18;35(3):369-384.e7
pubmed: 30799057
Mol Cell. 2016 Jul 21;63(2):218-228
pubmed: 27397683
Leukemia. 2020 Jul;34(7):1924-1928
pubmed: 32042080
ACS Chem Biol. 2017 Mar 17;12(3):825-832
pubmed: 28135068
Nat Biotechnol. 2016 Feb;34(2):184-191
pubmed: 26780180
BMC Bioinformatics. 2016 May 10;17:208
pubmed: 27161244
Invest New Drugs. 2001;19(3):219-27
pubmed: 11561678
Mol Cell. 2002 Dec;10(6):1511-8
pubmed: 12504025
J Med Chem. 1999 Sep 23;42(19):3789-99
pubmed: 10508428
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Biotechnol. 2016 Jun;34(6):631-3
pubmed: 27111720
Nat Rev Clin Oncol. 2020 Aug;17(8):457-474
pubmed: 32303702
Nat Chem Biol. 2017 Jun;13(6):675-680
pubmed: 28437394
Cancer. 2018 Jul 1;124(13):2758-2765
pubmed: 29660836
Science. 2017 Apr 28;356(6336):
pubmed: 28302793
Cell Chem Biol. 2021 Jul 15;28(7):1048-1060
pubmed: 33811812
J Clin Oncol. 2002 Aug 15;20(16):3508-21
pubmed: 12177112
Cancer Sci. 2005 Oct;96(10):721-8
pubmed: 16232205
Genome Biol. 2014;15(12):554
pubmed: 25476604
Ann Oncol. 2005 Jan;16(1):158-61
pubmed: 15598954
Genomics. 1999 Apr 15;57(2):310-5
pubmed: 10198174
Nature. 1994 Jun 23;369(6482):678-82
pubmed: 8208298
Cell. 2021 Jul 22;184(15):4032-4047.e31
pubmed: 34171309
Nat Commun. 2019 Jan 11;10(1):137
pubmed: 30635584
Genome Biol. 2006;7(7):R66
pubmed: 16869968
Nat Chem Biol. 2020 Jan;16(1):15-23
pubmed: 31819272
EMBO Rep. 2002 Feb;3(2):177-82
pubmed: 11818338
Nucleic Acids Res. 2020 Jul 2;48(W1):W488-W493
pubmed: 32246720
Methods. 2013 Jun 1;61(2):156-64
pubmed: 23607990
Mol Cell. 2018 Mar 1;69(5):773-786.e6
pubmed: 29499133
Clin Cancer Res. 2007 Mar 15;13(6):1816-22
pubmed: 17363538
Pharmacoeconomics. 2021 Nov;39(11):1243-1269
pubmed: 34368939
Cell Rep. 2013 Apr 25;3(4):1306-20
pubmed: 23602568
ESMO Open. 2019 May 24;4(3):e000505
pubmed: 31231569
Clin Cancer Res. 2004 Jul 15;10(14):4680-7
pubmed: 15269140
Cell. 2017 Feb 9;168(4):579-583
pubmed: 28187281
Mol Cell. 2019 Aug 22;75(4):849-858.e8
pubmed: 31442425
Oncogene. 2008 Dec;27 Suppl 1:S128-36
pubmed: 19641498
Acta Crystallogr D Struct Biol. 2016 Apr;72(Pt 4):497-511
pubmed: 27050129